Clin2
NCT07133815Possibly a fitNot yet recruiting

Long-term study of SHR-1918 for homozygous familial hypercholesterolemia

Homozygous Familial Hypercholesterolemia

Treatments studied

Part of Genetic & congenital, Hormones & metabolism clinical trials.

This trial tests the long-term safety and effectiveness of the drug SHR-1918. It is for people with homozygous familial hypercholesterolemia who have already benefited from this drug in a previous study.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
55 people
Ages
12 years and older
Study type
Interventional

Who can take part

  • You must have taken part in the earlier SHR-1918-301 study and completed the treatment.
  • Your doctors must have decided that you got benefit from the treatment in that study.
  • You cannot be allergic to SHR-1918 or any of its ingredients.
  • You must not have had cancer in the last 5 years.
  • You cannot have any serious medical conditions that could interfere with the trial.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06125847Recruiting· Early Phase 1
Gene therapy for inherited high cholesterol

This trial tests a one-time gene therapy (NGGT006) to treat a severe form of inherited high cholesterol that doesn't respond well to standard medications. It aims to lower cholesterol and reduce the risk of heart disease.

Xi'an, Shaanxi
NCT01109368Recruiting
Registry for people with inherited very high cholesterol

This trial is a registry that collects information from people with homozygous familial hypercholesterolemia (an inherited condition causing extremely high “bad” cholesterol). It may help researchers better understand the condition and support future studies.

New York, New York
NCT07591298Recruiting· Phase 2
SYH2070 injection for homozygous familial high cholesterol

This study tests a new injectable medication (SYH2070) designed to lower cholesterol in people with homozygous familial hypercholesterolemia—a genetic condition that causes extremely high cholesterol levels despite treatment. The goal is to see if this drug safely reduces cholesterol better than current options.

Changsha, Hunan
NCT07404553Recruiting· Phase 2/Phase 3
Study of SHR-1918 for high cholesterol not controlled by statins and PCSK9 inhibitors

This trial tests a new medicine, SHR-1918, for people whose bad cholesterol (LDL-C) stays high even when they take statins and another type of cholesterol-lowering drug called a PCSK9 inhibitor. It aims to see if this additional treatment can lower their cholesterol more effectively.

Nanjing, Jiangsu
NCT07349615Recruiting· Phase 3
Study of SHR-1918 for high triglycerides

This trial tests a new medication, SHR-1918, to lower high triglyceride levels. It may be an option for people with moderately elevated triglycerides and controlled cholesterol.

Shanghai, Shanghai Municipality
NCT07230730Recruiting· Phase 3
Testing a new drug for high cholesterol

This trial tests a new medication called SHR-1918 for people with high cholesterol who are already on statins. The goal is to see if it can further lower cholesterol and improve health.

Hangzhou, Zhejiang

Hear when a new Homozygous Familial Hypercholesterolemia trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.